← Back to Clinical Trials
Recruiting NCT06950593

NCT06950593 Transcutaneous Electrical Stimulation for Stroke Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06950593
Status Recruiting
Phase
Sponsor Shirley Ryan AbilityLab
Condition Upper Limb Hemiparesis Following Stroke
Study Type INTERVENTIONAL
Enrollment 14 participants
Start Date 2025-08-18
Primary Completion 2026-06-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Task Specific Training (TST)Transcutaneous electrical spinal cord stimulation (TESS)Sham transcutaneous electrical spinal cord stimulation (Sham TESS)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 14 participants in total. It began in 2025-08-18 with a primary completion date of 2026-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to evaluate the feasibility and impact of transcutaneous electrical stimulation of the spinal cord (TESS) on the recovery of post-stroke individuals who have upper limb hemiparesis. It will compare outcomes measures between individuals who receive upper limb task specific training with TESS and individuals who receive task specific training of the upper limb with Sham, or fake, TESS.

Eligibility Criteria

Inclusion Criteria: * 18 years or older * able and willing to give written consent and comply with study procedures * at least 6 months post-stroke * hemiplegia secondary to stroke * UE Fugle Meyer Assessment \<35 * not currently receiving regular occupational therapy services * participant has received clearance from physician to participate in study * participant has at least a rudimentary comprehension of English Exclusion Criteria: * botox injection in upper extremity within the last 4 months * modified ashworth score of 4 in any joint of the affected limb * pregnant or nursing * using a powered, implanted cardiac device for monitoring or support of heart function (i.e. pacemaker, defibrillator, or LVAD), or anti-spasticity implantable pumps, or cochlear implants * unhealed bone fractures * severe contractures in the upper extremities * active cancer or cancer remission less than 5 years * orthopedic dysfunction, injury, or surgery that would impact the individual's ability to use the upper extremities * recent procedure or operation of the spinal cord within the past year * traumatic brain injury or neurological conditions that would impact the study * skull fracture that has developed within the past 6 months * non-English speakers

Contact & Investigator

Central Contact

Mary Ellen Stoykov, PhD, OT

✉ mstoykov@sralab.org

📞 773-704-2422

Frequently Asked Questions

Who can join the NCT06950593 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Upper Limb Hemiparesis Following Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06950593 currently recruiting?

Yes, NCT06950593 is actively recruiting participants. Contact the research team at mstoykov@sralab.org for enrollment information.

Where is the NCT06950593 trial being conducted?

This trial is being conducted at Chicago, United States.

Who is sponsoring the NCT06950593 clinical trial?

NCT06950593 is sponsored by Shirley Ryan AbilityLab. The trial plans to enroll 14 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology